Status:

UNKNOWN

Chemotherapy and/or Hormone Therapy With or Without Zoledronate in Treating Women With Stage II or Stage III Breast Cancer

Lead Sponsor:

University of Sheffield

Conditions:

Breast Cancer

Metastatic Cancer

Eligibility:

FEMALE

18+ years

Phase:

PHASE3

Brief Summary

RATIONALE: Zoledronate may delay or prevent the formation of bone metastases. It is not yet known whether chemotherapy and/or hormone therapy are more effective with or without zoledronate in preventi...

Detailed Description

OBJECTIVES: Primary * Compare disease-free survival of women with stage II or III breast cancer at high risk of relapse treated with neoadjuvant or adjuvant chemotherapy and/or hormonal therapy with...

Eligibility Criteria

Inclusion

  • DISEASE CHARACTERISTICS:
  • Diagnosis of primary breast cancer, meeting 1 of the following staging criteria:
  • Stage II
  • Stage III
  • T stage ≥ T1
  • Receiving OR scheduled to receive chemotherapy and/or endocrine therapy
  • For patients receiving neoadjuvant therapy
  • Tumor \> 5 cm (T3), features of locally advanced disease (T4), OR biopsy-proven lymph node involvement (N1)
  • Scheduled to proceed to definitive surgery and/or radical radiotherapy with curative intent within 6 months of starting neoadjuvant therapy
  • No more than 30 days between initiation of neoadjuvant therapy and start of study drug
  • For patients receiving adjuvant therapy
  • Must have undergone complete primary tumor resection and treatment of axillary lymph nodes\*
  • Must have lymph node involvement
  • No prior neoadjuvant therapy\*\*
  • No more than 60 days since prior definitive surgery NOTE: \*Patients whose treatment plan includes further primary tumor resection and/or treatment of the axillary lymph nodes (e.g., clearance or radiotherapy) with curative intent after completion of chemotherapy are eligible provided the treatment is completed within 9 months of study entry
  • NOTE: \*\*Preoperative endocrine therapy with a duration of \< 30 days is not considered prior neoadjuvant therapy
  • No evidence of recurrent or metastatic disease
  • No history of breast cancer, except ductal carcinoma in situ or lobular carcinoma in situ
  • Hormone receptor status:
  • Not specified
  • PATIENT CHARACTERISTICS:
  • Age
  • 18 and over
  • Sex
  • Female
  • Menopausal status
  • Premenopausal or postmenopausal
  • Performance status
  • Karnofsky 80-100% OR
  • ECOG 0-1
  • Life expectancy
  • Not specified
  • Hematopoietic
  • Not specified
  • Hepatic
  • Not specified
  • Renal
  • Creatinine ≤ 1.5 times upper limit of normal
  • Other
  • Not pregnant or nursing
  • Fertile patients must use effective contraception
  • No active dental problems, including dental abscess or infection of the jaw bone (e.g., maxilla or mandible)
  • No prior or current diagnosis of osteonecrosis of the jaw
  • No other malignancy within the past 5 years (including prior contralateral breast cancer) except nonmelanoma skin cancer or curatively treated carcinoma in situ of the cervix
  • No history of disease with influence on bone metabolism, including any of the following:
  • Paget's disease of the bone
  • Primary hyperparathyroidism
  • Osteoporosis requiring treatment or likely to require treatment within the next 6 months
  • No other severe physical or psychological disease that would preclude study compliance
  • No known hypersensitivity to bisphosphonates
  • PRIOR CONCURRENT THERAPY:
  • Chemotherapy
  • See Disease Characteristics
  • Endocrine therapy
  • See Disease Characteristics
  • Radiotherapy
  • See Disease Characteristics
  • Surgery
  • See Disease Characteristics
  • More than 4 weeks since prior and no concurrent dental or jaw surgery (e.g., extractions or implants)
  • Dental fillings, teeth scaling and polishing, or minor gingival surgery within the past 4 weeks are allowed
  • Other
  • More than 1 year since prior bisphosphonates
  • More than 30 days since prior investigational drugs
  • No concurrent investigational drugs (i.e., not locally approved for any indication)

Exclusion

    Key Trial Info

    Start Date :

    August 1 2003

    Trial Type :

    INTERVENTIONAL

    End Date :

    Estimated Enrollment :

    Patients enrolled

    Trial Details

    Trial ID

    NCT00072020

    Start Date

    August 1 2003

    Last Update

    August 2 2013

    Active Locations (0)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 0 (0 locations)

    No Results Found

    We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.